IDONGESIT STEPHENS: Open Payments
NPI 1467964114 · CHINO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,731 in 85 payments from 14 companies in 2025. Trend: 2023 $1,250 · 2024 $1,770 · 2025 $1,731
Food & beverage: $1,731
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 19 | $447 |
| Vanda Pharmaceuticals Inc. | 13 | $264 |
| Otsuka America Pharmaceutical, Inc. | 11 | $208 |
| E.R. Squibb & Sons, L.L.C. | 10 | $165 |
| Teva Pharmaceuticals USA, Inc. | 8 | $136 |
| ABBVIE INC. | 4 | $96 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $84 |
| Neurocrine BioSciences, Inc. | 4 | $75 |
| Janssen Pharmaceuticals, Inc | 3 | $70 |
| Lundbeck LLC | 3 | $61 |
Products named: ARISTADA, REXULTI, HETLIOZ, COBENFY, LYBALVI, AUSTEDO XR, VRAYLAR, CAPLYTA.
Industry payments across CA — which companies pay providers there.
